SANUWAVE Health Q2 2024 Earnings Report

SANUWAVE Health EPS Results

• Actual EPS: $3.75
• Consensus EPS: N/A
• Beat/Miss: N/A
• One Year Ago EPS: N/A

SANUWAVE Health Revenue Results

• Actual Revenue: $7.16 million
• Expected Revenue: N/A
• Beat/Miss: N/A
• YoY Revenue Growth: N/A

SANUWAVE Health Announcement Details

• Quarter: Q2 2024
• Date: 8/12/2024
• Time: N/A

SANUWAVE Health (OTCMKTS:SNWV), a shock wave technology company, researches, develops, and commercializes noninvasive, high-energy, and acoustic shock waves for regenerative medicine and other applications in the United States and internationally. Its shockwaves are used to produce a biological response resulting in the body healing itself through the repair and regeneration of tissue, musculoskeletal, and vascular structures. The company's pulsed acoustic cellular expression systems, including dermaPACE system for treating diabetic foot ulcers and other chronic wounds; orthoPACE system for treating tendinopathies and acute and nonunion fractures; and Profile is used to provide solution for pain management in sports medicine and physical therapy. Its portfolio of wound treatment solutions provides patients with a noninvasive technology that boosts the body's normal healing and tissue regeneration processes. In addition, the company offers UltraMIST, non-contact and non-thermal ultrasound therapy device used to treat diabetic foot ulcers, pressure ulcers, venous leg ulcers, deep tissue pressure injuries, and surgical wounds. SANUWAVE Health, Inc. was founded in 2004 and is headquartered in Eden Prairie, Minnesota.